Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.
The monoclonal antibodies were isolated from the blood of a couple from Wuhan, China, who were diagnosed with COVID-19 after traveling to Toronto, Canada, in late January. They were two of the earliest confirmed cases of COVID-19 in North America.
During the past two years, VUMC researchers led by James Crowe, Jr., MD, and Robert Carnahan, PhD, have developed ultra-fast methods for discovering highly potent antiviral human monoclonal antibodies and validating their ability to protect small animals and non-human primates, all in less than three months.
Reporting last week in the journal Nature Medicine, the researchers and colleagues from across the country describe how they used this rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies against the surface spike (S) protein that enables SARS-CoV-2, the virus that causes COVID-19, to infect lung cells.
In a separate report published today in the journal Nature, VUMC scientists and their colleagues describe how two of the antibodies, COV2-2196 and COV2-2130, bind to distinct sites on the S protein and either alone or in combination reduce the viral “burden” in infected mice and protect them from weight loss and lung inflammation.
They also found that COV2-2196 and another potent antibody, COV2-2381, given alone protected rhesus macaques from SARS-CoV-2 infection. Collectively these results suggest that these monoclonal antibodies, either alone or in combination, “are promising candidates for prevention or treatment of COVID-19,” the researchers concluded.
Last month the global biopharmaceutical company AstraZeneca licensed one set of the antibodies described in the Nature paper for clinical evaluation and development. IDBiologics, a Nashville-based biotechnology firm, has licensed a separate set of the antibodies. Both companies are planning clinical trials this summer.
VUMC’s academic partners in the research included Washington University School of Medicine in St. Louis, Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, the University of North Carolina at Chapel Hill, Emory University in Atlanta, the University of Washington in Seattle, the University of Toronto, Canada, and Leipzig University in Germany.
In addition to AstraZeneca, corporate partners included California-based Berkeley Lights Inc., 10x Genomics and Twist Bioscience.
Major funding sources included DARPA, the Defense Advanced Research Projects Agency of the U.S. Department of Defense (DoD), the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Merck KGaA, Darmstadt, Germany, and the Dolly Parton COVID-19 Research Fund at Vanderbilt.
Crowe, who directs the Vanderbilt Vaccine Center (VVC), holds the Ann Scott Carell Chair in the Departments of Pediatrics and Pathology, Microbiology and Immunology at Vanderbilt. Carnahan is associate VVC director and associate professor of Pediatrics and Radiology and Radiological Sciences.
VVC research fellow Seth Zost, PhD, and Pavlo Gilchuk, PhD, VVC senior staff scientist, were the first authors of both papers.
Other Vanderbilt co-authors were Elad Binshtein, PhD, Joseph X. Reidy, MS, Andrew Trivette, MS, Rachel Nargi, Rachel Sutton, Naveen Suryadevara, PhD, Lauren Williamson, Elaine Chen, Taylor Jones, Samuel Day, Luke Myers, Benjamin Mueller, PhD, and Jens Meiler, PhD.
